JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 15, Issue 4 (2023)
Iran J War Public Health 2023, 15(4): 429-433 |
Back to browse issues page
Article Type:
Subject:
Ethics code: 141/KEPK-J/VIII/2022
History
Received: 2023/08/10 | Accepted: 2024/01/18 | Published: 2024/01/30
Received: 2023/08/10 | Accepted: 2024/01/18 | Published: 2024/01/30
How to cite this article
Hussein M, Safar A, Khalaf M, Mahmood M. Immunological and Biochemical Glimpses of Giardiasis in Thalassemic Patients. Iran J War Public Health 2023; 15 (4) :429-433
URL: http://ijwph.ir/article-1-1384-en.html
URL: http://ijwph.ir/article-1-1384-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Pathological Analysis, College of Science, Thi-Qar University, Thi-Qar, Iraq
2- Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq
3- Department of Pathological Analytics Science, College of Applied Medical Science, Shatrah University, Thi-Qar, Iraq
2- Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq
3- Department of Pathological Analytics Science, College of Applied Medical Science, Shatrah University, Thi-Qar, Iraq
Abstract (701 Views)
Aims: The present work seeks to ascertain immunological and biochemical characteristics in thalassemic individuals who have contracted giardiasis.
Materials & Methods: This experimental study was conducted at the Thalassemia Center in Thi-Qar province, Iraq, in 2022. Fifty patients (21 males and 29 females) and 20 healthy controls were investigated. Of the patients’ group, twenty-five were thalassemic and had giardiasis. The other 14 patients were thalassemic and free of giardia infection, and the remaining 11 patients were non-thalassemic but had giardia infection. Five ml of venous blood from each participant was withdrawn to determine WBCs, neutrophil activity, and levels of IL-6, iron, ferritin, and transferrin.
Findings: The levels of interleukin-6 in the three patient groups (28.20, 23.29, and 30.94pg/ml) were considerably higher than those in healthy controls (16.09pg/ml). In patient groups, there was a notable rise in WBCs but a notable fall in neutrophil activity. Additionally, a substantial increase in iron and ferritin was found, although transferrin was lower in the patients than in the control group.
Conclusion: The thalassemia and giardia patients have greater iron and ferritin levels but much lower transferrin levels than the healthy individuals.
Materials & Methods: This experimental study was conducted at the Thalassemia Center in Thi-Qar province, Iraq, in 2022. Fifty patients (21 males and 29 females) and 20 healthy controls were investigated. Of the patients’ group, twenty-five were thalassemic and had giardiasis. The other 14 patients were thalassemic and free of giardia infection, and the remaining 11 patients were non-thalassemic but had giardia infection. Five ml of venous blood from each participant was withdrawn to determine WBCs, neutrophil activity, and levels of IL-6, iron, ferritin, and transferrin.
Findings: The levels of interleukin-6 in the three patient groups (28.20, 23.29, and 30.94pg/ml) were considerably higher than those in healthy controls (16.09pg/ml). In patient groups, there was a notable rise in WBCs but a notable fall in neutrophil activity. Additionally, a substantial increase in iron and ferritin was found, although transferrin was lower in the patients than in the control group.
Conclusion: The thalassemia and giardia patients have greater iron and ferritin levels but much lower transferrin levels than the healthy individuals.
Keywords:
References
1. AlAyyar RM, AlAqeel AA, AlAwadhi MS. Prevalence of giardiasis and entamoeba species in two of the six governorates of Kuwait. J Parasitol Res. 2022;2022:1-6. [Link] [DOI:10.1155/2022/5972769]
2. Davis AN, Haque R, Petri WA., Jr Update on protozoan parasites of the intestine. Curr Opin Gastroentrol. 2002;18:10-4. [Link] [DOI:10.1097/00001574-200201000-00003]
3. Haque R. Human intestinal parasites. J Health Popul Nutr. 2007;25(4):387-91. [Link]
4. Khalaf MM, Hussein MH, Hafedh AA. Evaluation of IL-2, IL-4 and IL-10 levels in patients with Giardiasis. Ann Parasitol. 2021;67(4):697-702. [Link]
5. Jeske S, Bianchi TF, Moura MQ, Baccega B, Pinto NB, Berne MEA, et al. Intestinal parasites in cancer patients in the south of Brazil. Braz J Biol. 2018;78(3):574-8. [Link] [DOI:10.1590/1519-6984.175364]
6. Einarsson E, Ma'ayeh S, Svärd SG. An up-date on Giardia and giardiasis. Curr Opin Microbiol. 2016;34:47-52. [Link] [DOI:10.1016/j.mib.2016.07.019]
7. Minetti C, Chalmers RM, Beeching NJ, Probert C, Lamden K. Giardiasis. BMJ. 2016;355:i5369. [Link] [DOI:10.1136/bmj.i5369]
8. Haque R. Human intestinal parasites. J Health Popul Nutr. 2007;25(4):387-91. [Link]
9. Lauwaet T, Davids BJ, Reiner DS, Gillin FD. Encystation of Giardia lamblia: a model for other parasites. Curr Opin Microbiol. 2007;10(6):554-9. [Link] [DOI:10.1016/j.mib.2007.09.011]
10. Monjur A. Intestinal Parasitic Infections in 2023. Gastroenterology Res. 2023;16(3):127-40. [Link] [DOI:10.14740/gr1622]
11. M N Zafar 1, R Baqai, T Z Lodi, S Ahmad, W Ahmed, H Qureshi H, et al. Giardia lamblia in patients undergoing upper G.I. endoscopy. J Pak Med Assoc. 1991;41:74-5. [Link]
12. Rahav G, Volach V, Shapiro M, et al. Severe infections in thalassaemic patients: prevalence and predisposing factors Thalassaemia. Br J Haematol. 2006;133:667-74. [Link] [DOI:10.1111/j.1365-2141.2006.06082.x]
13. Rajarshi G, Avani K, Preeti M. Intestinal parasitic infections in beta-thalassemia major and aplastic anemia in a tertiary care center in western India. Int J Contemporary Med Res. 2016;3(9):2649-51. [Link]
14. Yakoob J, Jafri W, Shaikh H (2010). Is there an association of giardiasis with beta-thalassemia minor?. East J Med. 15(3);128-31. [Link]
15. Recalcati S, Cairo G. Macrophages and iron: A special relationship. Biomedicines. 2021.30;9(11):1585. [Link] [DOI:10.3390/biomedicines9111585]
16. Rahav G, Volach V, Shapiro M, et al. Severe infections in thalassaemic patients: prevalence and predisposing factors Thalassaemia. Br J Haematol. 2006;133:667-74. [Link] [DOI:10.1111/j.1365-2141.2006.06082.x]
17. Ladis V, Chouliaras G, Bedousi H, et al. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445-50. [Link] [DOI:10.1196/annals.1345.067]
18. Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2009;1(1):e2009028. [Link] [DOI:10.4084/MJHID.2009.028]
19. Pinto VM, Forni GL. Management of iron overload in beta-thalassemia patients: clinical practice update based on case series. Int J Mol Sci. 2020;21(22):8771. [Link] [DOI:10.3390/ijms21228771]
20. Lee WS, Toh TH, Chai PF, Soo TL. Self‐reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias. J Paediatr Child Health. 2011;47(8):535‐40 [Link] [DOI:10.1111/j.1440-1754.2011.02017.x]
21. Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al‐Momen A. Immunological evaluation of β‐thalassemia major patients receiving oral iron chelator deferasirox. J Coll Physicians Surg Pak. 2014;24(7):467‐71. [Link]
22. Quintiliani L, Mastromonaco A, Giuliani E, et al. Immune profile alterations in thalassaemic patients. Boll Ist Sieroter Milan. 1983;62(6):524‐30 [Link]
23. Sari TT, Gatot D, Akib AA, Bardosono S, Hadinegoro SR, Harahap AR. Immune response of thalassemia major patients in Indonesia with and without splenectomy. Acta Med Indones. 2014;46(3):217-25. [Link]
24. Abo-Shanab AM, El-Desouky N, Kholoussi G, El-Kamah AA, Fahmi H. Evaluation of neopterin as a prognostic factor in patients with beta-thalassemia, in comparison with cytokines and immunoglobulins. Arch Hellenic Med. 2015;32(1):60-5. [Link]
25. El-Beshlawy A, Youssry I. Prevention of hemoglobinopathies in Egypt. Hemoglobin, 2009;33(1):S14-20. [Link] [DOI:10.3109/03630260903346395]
26. Stryer L. Biochemistry. 4th edition. New York: Freeman and Company; 1997. [Link]
27. Elaine M, Jeanine M, Larry J. Rodak's hematology. 5th edition. London: Saunders; 2015. pp. 307-9. [Link]
28. Fleming R, Ponka P. Iron overload in human disease. New Eng J Med. 2012;366(4):348-59. [Link] [DOI:10.1056/NEJMra1004967]
29. Herbert V, Shaw S, Jayatilleke E. High serum ferritin protein does not distinguish iron overload from inflammation, but a new assay, high serum ferritin-iron, does. Stem Cell. 1997;15(4):291-6. [Link] [DOI:10.1002/stem.150291]
30. Al-Kataan M, Al-Rasheed S, Ahmed F. Serum iron status in beta-thalassemic patients with clinical signs of iron overload. Tikrit Med J. 2009;15(1):9-12. [Link]
31. Zilva J, Pannall P. Clinical chemistry in diagnosis and treatment. 4th edition. London: Loyd-Luke Ltd; 1984. [Link]
32. Bandyopadhyay U, Kundu D, Sinha A, Banerjee K, Bandyopadhyay R, Mandal T, et al. Conservative management of Beta-thalassemia major cases in the sub-division level hospital of rural West Bengal, India. J Nat Sci Biol Med. 2013;4(1):108. [Link] [DOI:10.4103/0976-9668.107269]
33. Cappellini M, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia, 2nd Revised edition. Nicosia (CY): Thalassaemia International Federation; 2008. [Link]
34. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27(7):681-7. [Link] [DOI:10.1093/ajcn/27.7.681]
35. Harris DC. Iron exchange between ferritin and transferrin in vitro. Biochemistry. 1978;17(15):3071-8. [Link] [DOI:10.1021/bi00608a020]
36. Blrgegård G, Hålxgren R, Killander A, Strömberg A, Venge P, Wide L. Serum ferritin during infection: a longitudinal study. Scand J Haematol. 1978;21(4):333-40. [Link] [DOI:10.1111/j.1600-0609.1978.tb00374.x]
37. Rothwell RS, Davis P. Relationship between serum ferritin, anemia, and disease activity in acute and chronic rheumatoid arthritis. Rheumatol Int. 1981;1:65-7. [Link] [DOI:10.1007/BF00541155]
38. Reissmann KR, Dietrich MR. On the presence of ferritin in the peripheral blood of patients with hepatocellular disease. J Clin Invest. 1956;35(6):588-95. [Link] [DOI:10.1172/JCI103312]
39. Jacobs A. Serum ferritin and malignant tumours. Med Oncol Tumor Pharmacother. 1984;1:149-56. [Link] [DOI:10.1007/BF02934136]
40. Lauffer RB, editor. Iron and human disease. Boca Raton, FL: CRC press; 1992. [Link]
41. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr. 1974;27(7):681-7. [Link] [DOI:10.1093/ajcn/27.7.681]
42. Pootrakul P, Josephson B, Huebers HA, et al. Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood. 1988;71:1120-3. [Link] [DOI:10.1182/blood.V71.4.1120.1120]
43. Rothwell RS, Davis P. Relationship between serum ferritin, anemia and disease activity in acute and chronic rheumatoid arthritis. Rheumatol Int. 1981;1:65-7. [Link] [DOI:10.1007/BF00541155]
44. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P, Grady RW, Bowman B, Gunter EW. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem cells. 1997;15(4):291-6. [Link] [DOI:10.1002/stem.150291]